Evaluation of novel radiotherapy technologies: What evidence is needed to assess their clinical and cost effectiveness, and how should we get it?

The Lancet Oncology

Volumn 13, Issue 4, 2012, Pages

  Van Loon, Judith ^a,c   Grutters, Janneke ^b   Macbeth, Fergus ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; ECONOMIC ASPECT; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; OBSERVATIONAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; REIMBURSEMENT; REVIEW; STEREOTACTIC TREATMENT; UTERINE CERVIX CANCER;

COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, RADIATION; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, ECONOMIC; NEOPLASMS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859130818     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70379-5     Document Type: Review

References (74)

1. Mattsson S, Brahme A, Carlsson J, et al. Swedish Cancer Society radiation therapy research investigation. Acta Oncol 2002, 41:596-603.
2. Bentzen SM High-tech in radiation oncology: should there be a ceiling?. Int J Radiat Oncol Biol Phys 2004, 58:320-330.
3. Goitein M, Cox JD Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol 2008, 26:175-176.
4. Lievens Y, Van den Bogaert W Proton beam therapy: too expensive to become true?. Radiother Oncol 2005, 75:131-133.
5. Bentzen SM Randomized controlled trials in health technology assessment: overkill or overdue?. Radiother Oncol 2008, 86:142-147.
6. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009, 27:3868-3874.
7. Drummond MF, Mason AR European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 2007, 25:191-195.
8. Medical technologies evaluation programme: process guide National Institute for Health and Clinical Excellence, (accessed Jan 27, 2012). http://www.nice.org.uk/media/4E0/F7/MedicalTechnologiesEvaluationProgrammeProcessGuide.pdf.
9. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12:933-980.
10. Rawlins MD, Chalkidou K The opportunity cost of cancer care: a statement from NICE. Lancet Oncol 2011, 12:931-932.
11. Konski A, Watkins-Bruner D, Feigenberg S, et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66:408-415.
12. Peeters A, Grutters JP, Pijls-Johannesma M, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol 2010, 95:45-53.
13. Goitein M, Jermann M The relative costs of proton and X-ray radiation therapy. Clin Oncol (R Coll Radiol) 2003, 15:S37-S50.
14. Huang D, Xia P, Akazawa P, et al. Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys 2003, 56:158-168.
15. Xia P, Fu KK, Wong GW, et al. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2000, 48:329-337.
16. De Meerleer GO, Vakaet LA, De Gersem WR, et al. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 2000, 47:639-648.
17. Baumert BG, Lomax AJ, Miltchev V, et al. A comparison of dose distributions of proton and photon beams in stereotactic conformal radiotherapy of brain lesions. Int J Radiat Oncol Biol Phys 2001, 49:1439-1449.
18. Cozzi L, Fogliata A, Lomax A, et al. A treatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours. Radiother Oncol 2001, 61:287-297.
19. Fogliata A, Bolsi A, Cozzi L Critical appraisal of treatment techniques based on conventional photon beams, intensity modulated photon beams and proton beams for therapy of intact breast. Radiother Oncol 2002, 62:137-145.
20. Isacsson U, Lennernas B, Grusell E, et al. Comparative treatment planning between proton and x-ray therapy in esophageal cancer. Int J Radiat Oncol Biol Phys 1998, 41:441-450.
21. Lee CH, Tait D, Nahum AE, et al. Comparison of proton therapy and conformal X-ray therapy in non-small cell lung cancer (NSCLC). Br J Radiol 1999, 72:1078-1084.
22. St Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004, 58:727-734.
23. De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol 2005, 77:5-10.
24. van Loon J, Offermann C, Bosmans G, et al. 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. Radiother Oncol 2008, 87:49-54.
25. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003, 57:853-863.
26. Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008, 9:367-375.
27. Brada M, Pijls-Johannesma M, De Ruysscher D Current clinical evidence for proton therapy. Cancer J 2009, 15:319-324.
28. Glimelius B, Montelius A Proton beam therapy: do we need the randomised trials and can we do them?. Radiother Oncol 2007, 83:105-109.
29. Zietman A, Goitein M, Tepper JE Technology evolution: is it survival of the fittest?. J Clin Oncol 2010, 28:4275-4279.
30. Bonastre J, Noel E, Chevalier J, et al. Implications of learning effects for hospital costs of new health technologies: the case of intensity modulated radiation therapy. Int J Technol Assess Health Care 2007, 23:248-254.
31. Wild C, Langer T Emerging health technologies: informing and supporting health policy early. Health Policy 2008, 87:160-171.
32. Ploquin NP, Dunscombe PB The cost of radiation therapy. Radiother Oncol 2008, 86:217-223.
33. Dunscombe P, Roberts G, Walker J The cost of radiotherapy as a function of facility size and hours of operation. Br J Radiol 1999, 72:598-603.
34. Lievens Y, van den Bogaert W, Kesteloot K Activity-based costing: a practical model for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57:522-535.
35. Mobaraki A, Ohno T, Yamada S, et al. Cost-effectiveness of carbon ion radiation therapy for locally recurrent rectal cancer. Cancer Sci 2010, 101:1834-1839.
36. Lundkvist J, Ekman M, Ericsson SR, et al. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol 2005, 44:850-861.
37. Grutters JP, Pijls-Johannesma M, Ruysscher DD, et al. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev 2010, 36:468-476.
38. Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol 2007, 25:3603-3608.
39. Glatstein E, Glick J, Kaiser L, et al. Should randomized clinical trials be required for proton radiotherapy? An alternative view. J Clin Oncol 2008, 26:2438-2439.
40. Goitein M Trials and tribulations in charged particle radiotherapy. Radiother Oncol 2010, 95:23-31.
41. Macbeth FR, Williams MV Proton therapy should be tested in randomized trials. J Clin Oncol 2008, 26:2590-2591.
42. Suit H, Kooy H, Trofimov A, et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol 2008, 86:148-153.
43. Tepper JE Protons and parachutes. J Clin Oncol 2008, 26:2436-2437.
44. Rawlins M De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008, 372:2152-2161.
45. Meropol NJ A renewed call for equipoise. J Clin Oncol 2007, 25:3392-3394.
46. Freedman B Equipoise and the ethics of clinical research. N Engl J Med 1987, 317:141-145.
47. Lodge M, Pijls-Johannesma M, Stirk L, et al. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol 2007, 83:110-122.
48. VanderWeele TJ, Mukherjee B, Chen J Sensitivity analysis for interactions under unmeasured confounding. Stat Med 2011, published online Oct 4, 2011. 10.1002/sim.4354.
49. Helfand M, Tunis S, Whitlock EP, et al. A CTSA agenda to advance methods for comparative effectiveness research. Clin Transl Sci 2011, 4:188-198.
50. van Stiphout RG, Lammering G, Buijsen J, et al. Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother Oncol 2011, 98:126-133.
51. Roelofs E, Persoon L, Qamhiyeh S, et al. Design of and technical challenges involved in a framework for multicentric radiotherapy treatment planning studies. Radiother Oncol 2010, 97:567-571.
52. Zurlo A, Lomax A, Hoess A, et al. The role of proton therapy in the treatment of large irradiation volumes: a comparative planning study of pancreatic and biliary tumors. Int J Radiat Oncol Biol Phys 2000, 48:277-288.
53. Tubiana M, Eschwege F Conformal radiotherapy and intensity-modulated radiotherapy: clinical data. Acta Oncol 2000, 39:555-567.
54. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010, 76:S3-S9.
55. Ramaekers BL, Pijls-Johannesma M, Joore MA, et al. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons. Cancer Treat Rev 2011, 37:185-201.
56. Claxton K, Posnett J An economic approach to clinical trial design and research priority-setting. Health Econ 1996, 5:513-524.
57. Eckermann S, Willan AR Expected value of information and decision making in HTA. Health Econ 2007, 16:195-209.
58. Palmer S, Smith PC Incorporating option values into the economic evaluation of health care technologies. J Health Econ 2000, 19:755-766.
59. Grutters JP, Abrams KR, De Ruysscher D, et al. When to wait for more evidence? Real options analysis in proton therapy. Oncologist 2011, 16:1752-1761.
60. Briggs A, Ritchie K, Fenwick E, et al. Access with evidence development in the UK: past experience, current initiatives and future potential. Pharmacoeconomics 2010, 28:163-170.
61. Chalkidou K, Lord J, Fischer A, et al. Evidence-based decision making: when should we wait for more information?. Health Aff (Millwood) 2008, 27:1642-1653.
62. Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004, 22:857-876.
63. Black N Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996, 312:1215-1218.
64. Erridge SC, Murray B, Williams L, et al. Improved survival from lung cancer in British Columbia compared to Scotland: are different treatment rates the whole story?. Lung Cancer 2009, 64:358-366.
65. Macbeth F Measuring the outcomes of lung cancer treatment. J Thorac Oncol 2008, 3:455-456.
66. Blettner M, Sauerbrei W, Schlehofer B, et al. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 1999, 28:1-9.
67. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000, 283:2008-2012. for the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.
68. Grutters JP, Kessels AG, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 2010, 95:32-40.
69. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. The EuroQol Group.
70. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med 2003, 163:1637-1641.
71. Deasy JO, Bentzen SM, Jackson A, et al. Improving normal tissue complication probability models: the need to adopt a " data-pooling" culture. Int J Radiat Oncol Biol Phys 2010, 76:S151-S154.
72. Sculpher M, Claxton K Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty: when is there sufficient evidence?. Value Health 2005, 8:433-446.
73. Griffin SC, Claxton KP, Palmer SJ, et al. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ 2011, 20:212-224.
74. Mowatt G, Bower DJ, Brebner JA, Cairns JA, Grant AM, McKee L When and how to assess fast-changing technologies: a comparative study of medical applications of four generic technologies. Health Technol Assess 1997, 1:1-149.